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ABSTRACT 
Myocardial infarction, more commonly known as heart attack, remains one of 
the world's most prominent health challenges, despite many breakthroughs in 
cardiovascular medicine. In fact, current therapeutic approaches only help to relieve 
the disease symptoms, restoration of function to the damaged heart is still formidable. 
To enhance the function of the damaged heart, cell transplantation may be an effective 
therapy. Pluripotent embryonic stem (ES) cells have unique ability to differentiate into 
cardiomyocytes and therefore are now being explored as a potential source of cardiac 
cells for future therapy. However, under conventional method of differentiation, the 
yield of cardiomyocytes in ES cell differentiation culture remains low. To increase the 
yield of cardiomyocytes, it is therefore important to understand the mechanism 
underlying cardiac differentiation of ES cells. 
Reactive oxygen species (ROS) including hydrogen peroxide (H2O2) and 
superoxide anion (O2.) as well as reactive nitrogen species (RNS) such as nitric oxide 
(NO), have been identified as important mediators in the regulation of signal 
transduction processes involved in cell growth and differentiation. Here, we 
hypothesize that ROS, by acting as signaling molecules, regulate the differentiation of 
mouse ESCs into cardiac lineage. By using flow cytometry and confocal microscopy, 
the levels of endogenous ROS was found to change during the initial course of ESC 
vii 
differentiation, with a peak of ROS expression at differentiation day 3-4, a period 
during which cardiac transcriptional factors start to express as reported by previous 
studies. Interestingly, exogenous application of H2O2 was found to lead to an earlier 
appearance of spontaneously beating phenotype in differentiating embryoid bodies. In 
contrast, application of NO by sodium nitroprusside (NO donor) led to a decrease in 
the percentage of spontaneously beating embryoid bodies. The results indicate that 
different reactive species have differential effects on cardiac differentiation. With 
real-time PGR and western blotting, both mRNA and protein expression levels of 
cardiac structural genes，including a-actinin, a-myosin heavy chain, cardiac troponin 
T and cardiac actin were found to have increased in various H202-treated samples. In 
addition, the expressions of several transcription factors, including GATA-binding 
protein 4 (GATA-4), myocyte enhancer factor 2C (MEF2C), heart and neural crest 
derviatives expressed 1 (HANDl), serum response factor (SRF), specificity protein 1 
(Spl), and activator protein l (AP-l) were also found to have elevated in respective 
HiOi-treated samples. This supports our hypothesis that ROS play a role in the 
differentiation of mouse ESCs into cardiac lineage. 
Our present investigation provides a comprehensive profile of the effects of H2O2 
on the expression of cardiac transcription factors and structural proteins. The novel 
information generated in this study shall provide insights into the possible strategies 
viii 
of enhancing cardiac differentiation of ES cells. Future study will be needed to 
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CHAPTER ONE INTRODUCTION 
1.1 Embryonic Stem (ES) Cells 
Embryonic stem (ES) cells were first successfully isolated from mouse 
almost three decades ago (Martin, 1981), and have later been obtained from other 
species including rat (lannaccone et al., 1994), rabbit (Graves and Moreadith, 
1993), rhesus monkeys (Thomson and Marshall, 1998) and human (Thomson et 
al., 1998). ES cells are originated from the inner cell mass (ICM) of an early 
mammalian embryo called blastocyst. The derivation process involves plating of 
the ICM on mouse embryonic fibroblasts (MEF) and expansion of the colonies 
into established ES cell lines (Fig.l). 
1.1.1 Characteristics of ES Cells 
ES cells can be distinguished from other cell types by three unique properties 
(Keller, 2005, Pera et al., 2000). 
First, ES cells are unspecialized. ES cells do not possess any tissue-specific 
structures for carrying out specialized functions. For examples, ES cell cannot fire 
action potentials for information transmission like a nerve cell, nor secrete insulin 
for blood glucose regulation like a pancreatic islet cell. However, unspecialized 
ES cells can eventually give rise to a wide variety of specialized cell types upon 
1 
differentiation. 
Second, ES cells are capable of long-term self-renewal. A starting population 
of ES cells can proliferate indefinitely in culture and continue to remain 
unspecialized, like their parent cells. 
Third, ES cells are pluripotent. ES cells are the master cells of our body, 
having the remarkable capability to differentiate into any of the three germ layers: 
endoderm, mesoderm or ectoderm, and giving rise to a versatility of cell types like 
pancreatic islet cells, hematopoietic cells, hepatic cells, neurons, cardiomyocytes 
and so on and so forth. 
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Fig. I A schematic diagram showing the derivation of ES cell line and its differentiation 
potential. Adopted from Expert Reviews in Molecular Medicine, 2005 Cambridge University 
Press 
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1.1.2 Therapeutic Potential of Embryonic Stem Cells 
The uniqueness of ES cells makes them a promising candidate for future therapy 
{Fig. 2). For instance, abnormal cell division and differentiation have been known to 
be the main contributors for common diseases like cancer and birth defect. A more 
thorough understanding of the genetic and molecular controls on the proliferation and 
differentiation of ES cells into specialized tissues may give us insight on how such 
diseases arise and suggest new strategies for therapy. 
ES cells can also be used as a tool for drug testing and screening (Bremer and 
Hartung, 2004, Kress, 2008). Specific cell populations generated from directed 
differentiation of pluripotent ES cell lines, like hepatocytes and neurons, can be used 
for screening new tissue-targeted drugs to identify potential candidates as therapeutics. 
Meanwhile, before new drugs can go forward for clinical trials, it is necessary for the 
chemical compound in the drug to undergo thousands of toxicity tests. The 
availability of pluripotent ES cells allows screening of potentially dangerous side 
effects in definite cell type during drug development to weed out harmful compounds 
(Rolletschek et al.，2004). 
Perhaps, the most important application of ES cells lies in the generation of 
desired cell populations for cell-based therapy. Today, an increasing number of people 
are suffering from diseases like heart disease, diabetes mellitus, Parkinson's and 
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Alzheimer's disease, which are caused by permanent dysfunction or death of a few 
cell types. Unfortunately, current therapeutic approaches only help relieve disease 
symptoms, restoration to the function of the affected tissue remains formidable. 
Recent advances in directed differentiation of ES cells into specific cell types offer the 
possibility of a renewable source of replacement cells for life-long treatment. 
The Promise of Stem Cell Research 
Identify drug Understanding 
targets and ^ Study cell prevention & 
test potential ， differentiation treatment of 
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Fig.2 A schematic diagram showing the promise of stem cell research. Adopted from 
California Parkinson's Group, 2007 (http://www.calparkinsons.org/downloacIs.php) 
LL3 Myocardial Infarction and ES Cells 一 derived Cardiomyocytes 
Myocardial infarction (MI), commonly known as a heart attack, has been the 
leading cause of morbidity and mortality in developed countries during the past few 
decades. In the United States, approximately 1.3 million cases of MI are reported each 
4 
year, with an annual death rate of around 500,000 — 700,000 patients (World Health 
Organization, http://www.who.int/cardiovascular_diseases/en/). Given the increasing 
popularity of tobacco smoking and high-fat diet consumption, MI is considered to be 
a significant health concern in the century. 
MI is resulted from the accumulation of an atherosclerotic plaque in the inner 
lining of the coronary artery, which suddenly ruptures, forming a thrombus that 
acutely occludes the artery and prevents blood flow downstream. This can occur in 
minutes. Without prompt treatment, oxygen deprivation due to impairment of blood 
flow will trigger permanent damage or even death of myocardium (Fig. 3). Attempting 
to sustain cardiac output, the overloading of blood flow and overstretching of viable 
cardiomyocytes would lead to heart failure, and eventual death of patient. 
3H.IIIJJIIILillJJJ 
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Fig. 3 A schematic diagram showing the cause of myocardial infarction. Adopted from 
American Heart Association, 1999 (http://www.fda.gOv/fdac/features/l999/attack.html) 
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Given the fact that the resident cardiac stem cells have inadequate native 
capacity for renewal and repair, cell transplantation strategies using ES cells derived 
cardiomyocytes therefore shed some light on future therapy (Dai and Kloner, 2006, 
Oh, 2005). On-going researches have been focusing on the efficiency and efficacy of 
generating a pure population of functional cardiomyocytes from ES cells as well as 
transplanting those cells into animal models. Preliminary researches in mice indicate 
that transplantation of ES cells-derived cardiomyocytes into the injured heart can have 
beneficial effects such as rescue of ischemic myocardium and meanwhile partial 
re-muscularization of infarcts (Laflamme et al., 2007, Rubait and Field, 2006). 
Whether the beneficial effects are caused by the direct incorporation of transplanted 
cells into the cardiac muscle cells or by the secretion of growth factors is actively 
under investigation. These promising results demonstrate how ES cells may one day 
become the saviors to repair damaged heart and rescue lives, though much more 
researches are further needed for safety assessment and efficacy improvement. 
1.1.4 Current Hurdles of Using ES cells-derived Cardiomyocytes for Research 
and Therapeutic Purposes 
While ES cells-derived cardiomyocytes show great potential in revolutionizing 
the treatment for MI, there is a myriad of technical hurdles to be overcome before ES 
cell-based therapy can enter the clinic {Fig. 4). Problems currently encountered 
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includes (a) low efficiency in isolation and purification of desired cell types from 
heterogeneous cell population in vitro; (b) low yield of cardiomyocytes obtained 
under conventional method of differentiation; (c) lack of data in large animal models 
such as swine, canine and primates; (d) lack of better feeder cells for culturing human 
ES cells so as to avoid the risk of transmitted pathogens from the animal feeder cells; 
(e) functional integration of transplanted graft in vivo; (f) tumor formation; as well as 
(g) immune rejection (Doss et al.，2008, Zhang and Pasumarthi, 2008, Swijnenburg et 
al., 2007). Intensive researches are certainly needed so as to jump over these hurdles 
one by one. 
Blastocyst hESC hESC-derived cardiac cells Transplantation 
Derivation Culture Differentiation Delivery 
• Reproducible isolation • (Epi)genetlc stability • Reproducible cardiac • Intramuscular/ 
techniques differentiation system Inlracoronary/intravenous? 
• Ethical considerations • Animal-free culture • Engineered scaffolds? 
environment 
Purificstion Integration 
• Teratoma formation • Electromechanical coupling 
• Paracrine function 
1 Survival 
• Non-specific cell death 
Cufietn Opinton in BkXechnoiogY 
Fig. 4 A schematic diagram outlining several areas of concern in derivation, culture, 
differentiation, purification, delivery, integration, and survival (Swijnenburg et al” 2007) 
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1.2 Transcription Factors for Cardiac Development 
The role of transcription factors in regulating cardiac differentiation of ES cells 
is still not well understood. However, it becomes increasingly clear from in vivo 
studies on heart development that the following transcription factors have critical 
contributions to the cardiac morphogenetic process. Many of these transcription 
factors have been demonstrated to be ROS-sensitive in a variety of cell populations 
(Akiba et a l , 2003，Aragno et al.，2006, Buggisch et al., 2007, Li et al., 2006，Hsu et 
al., 2004). It is therefore of special interest to investigate if ROS can mediate their 
actions through these cardiac transcription factors to affect differentiation of mouse 
ES cells into cardiac lineage. 
1.2.1 GATA-binding Protein 4 (GATA-4) 
GATA-4 is a zinc finger-containing transcription factor. It has a highly conserved 
DNA-binding domain that directly binds to the nucleotide sequence (A/T)GATA(A/G). 
It also has a potent transcriptional activation domain and domains that mediate its 
interaction with other transcriptional co-factors (Molkentin, 2000). GATA-4 is known 
to be important for differentiation of extra-embryonic endoderm (Soudais et al., 1995, 
Duncan, 2005). GATA-4 knockout mice died between embryonic (E) days 7.0 and 9.5 
due to defects in extra-embryonic endoderm, endoderm and ventral morphogenesis 
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(Molkentin et al., 1997, Kuo et al., 1997). To avoid this embryonic lethality and to 
investigate the role of GATA-4 in heart development, tetraploid embryo 
complementation was employed (Watt et al., 2004). When compare with GATA-4 
knockout mice, the embryos generated by this complementation method can further 
develop; the GATA-4~^~ ES cells/embryos complemented with wild-type visceral 
endoderm showed hypoplastic ventricles and a loss of the proepicardium, and died 
only at E9.5 (Watt et al., 2004). Similarly, mice with cardiac-specific conditional 
knockout of GATA-4 also showed hypoplastic ventricles and embryonic lethality (Pu 
et al., 2004, Oka et al., 2006). These studies indicate the importance of GATA-4 in 
regulating heart development and differentiation (Molkentin, 2000, Pikkarainen et al., 
2004). 
Previous studies showed that GATA-4 is a transcriptional regulator of numerous 
cardiac specific genes; it interacts with the GATA sites of different cardiac specific 
gene promoters to stimulate cardiac muscle-specific gene expression. GATA-4 was 
reported to bind to the promoters of atrial natriuretic peptide (ANP) (Charron et al., 
1999), b-type natriuretic peptide (BNP) (Charron et al., 1999), a-myosin heavy chain 
(a-MHC) (Molkentin et al., 1994, Charron et a l , 1999), P-myosin heavy chain 
(P-MHC) (Hasegawa et al., 1997, Charron et al., 1999)，cardiac troponin I (cTnl) 
(Murphy et al., 1997, Di Lisi et al., 1998，Bhavsar et al., 2000) and cardiac actin 
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(c-actin) (Sepulveda et al., 1998). 
1.2.2 Myocyte Enhancer Factor 2C (MEF2C) 
MEF2C belongs to the myocyte enhancer factor 2 (MEF2) family, which 
possesses in its N-terminus a MADS (MCMl, Agamous, Deficiens, and SRF) domain 
and a highly conserved MEF2-specific domain. These two domains govern direct 
dimerization and subsequent binding to their cognate DNA sequence 
CAT(A/T)4TAG/A (Black and Olson, 1998，McKinsey et al., 2002). Robustly 
expressed in cardiac precursor cells and differentiated cardiomyocytes during 
embryogenesis (Edmondson et al., 1994), MEF2C contributes essentially in 
cardiogenic development. Targeted inactivation and deletion of MEF2C in mice led to 
arrested right ventricular formation, abnormal morphogenesis of heart tube looping as 
well as embryonic lethality at E9.5. Meanwhile, a subset of cardiac genes has been 
found to be down-regulated in MEF2C-mx\\ embryos (Liu et al., 2001, Lin et al., 
1997). Consistently, MEF2C has been demonstrated to regulate the promoter activity 
of various cardiac genes, including myosin light chain 2 ventricular isoform (MLC2v), 
cardiac troponin T (cTnT), cTnl and a-MHC (Black and Olson, 1998, Bhavsar et al., 
2000). 
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1.2.3 NK2 Transcription Factor Related, Locus 5 (Nkx2.5) 
Nkx2.5 is a homeobox-containing transcription factor with a helix-tum-helix 
motif that binds specifically to the consensus DNA sequence T(C/T)AAGTG (Chen 
and Schwartz, 1995). It was firstly identified as a mammalian homologue of tinman in 
Drosophila, which was found to play a leading role in the development of dorsal 
vessel, an equivalence to the vertebrate heart (Lints et al., 1993, Komuro and Izumo, 
1993). Similar to GATA-4 and MEF2C, mutations or disruption of Nkx2.5 in mice 
resulted in a spectrum of congenital heart defects, accompanied by a reduced 
expression of several cardiac genes (including MLC2v, ANP, BNP, MEF2C and 
Iroquois homeobox gene 4) (Akazawa and Komuro, 2003). In mice, 
profound embryonic lethality was observed at E9.5 - 11.5 due to heart tube 
malformation at the initial stage of looping (Tanaka et al., 1999, Lyons et al., 1995). In 
addition, ANP (Durocher et a l , 1996，Shiojima et a l , 1999) and a-actinin (Chen and 
Schwartz, 1996) have been shown to be the direct downstream targets for Nkx2.5, 
suggesting a vital role of this transcription factor for cardiac development. 
1.2.4 Heart and Neural Crest Derivatives Expressed 1 / 2 (HANDl / 2) 
The HAND family encodes highly conserved basic helix-loop-helix (bHLH) 
transcription factors - HANDl and HAND2 (also known as eHAND and dHAND 
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respectively) that have distinctive roles in cardiac and extra-embryonic development 
(Srivastava, 1999). In mice, HAND2 is highly expressed in the developing right 
ventricle, with lower level in both the atria and left ventricle (Thomas et al., 1998). 
Targeted disruption of HAND2 led to embryonic lethality at E10.5 due to right 
ventricular hypoplasia and vascular malformations (Srivastava et al., 1997, Yamagishi 
et al., 2000). On the contrary, HANDl is expressed predominantly in left ventricle 
(Thomas et al., 1998, Biben and Harvey, 1997) but HAND J-nuU mice died at E8-8.5 
from placental and extra-embryonic abnormality, which aborts analysis of its potential 
role in later stages of cardiac development (Riley et al., 1998, Firulli et al., 1998). 
Nevertheless, the generation of HANDl-null chimeric embryos has revealed a 
possible role of HANDl in the morphogenesis of heart tube looping, since the 
embryos died at El0.5 from defects in cardiac looping (Riley et al., 1998, Riley et a l , 
2000). Further functions of HANDl have remained elusive. Consistently, studies in 
chick and zebrafish embryos also exhibited the potential participation of HANDl and 
HAND2 in cardiac development (Srivastava et al., 1995, Yelon et al., 2000). 
At present, only a limited number of direct downstream targets for HAND 
transcription factors have been identified. Binding with p300, HAND2 interacts with 
GATA-4 to elicit synergistic trans-activation of the ANP, BNP and a-MHC promoters 
(Dai et a l , 2002). Similarly, HANDl interacts with Nkx2.5 to synergistically 
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trans-activate the ANP promoter (Thattaliyath et al., 2002). 
1.2.5 T-box Protein 5 (Tbx5) 
Tbx5 is a T-box containing transcription factors important for the proper 
development of heart and limbs. Dominant mutations in Tbx5 result in 
haplo-insufficiency that causes Holt-Oram syndrome (HOS), an inherited human 
disease characterized by congenital heart defects, conduction-system abnormalities as 
well as upper limb deformities of variable severity (Li et al., 1997, Basson et al., 
1997). Homozygous Tbx5-knockout mice showed embryonic lethality at E9.5 due to 
arrested cardiac development, suggesting a pivotal role for Tbx5 in early heart 
morphogenesis. On the other hand, heterozygous Tbx5-knockout mice developed 
abnormal heart and limbs and also displayed a unique gene expression pattern 
showing its dosage sensitivity during cardiogenesis (Bruneau et al., 2001, Mori et al., 
2006). In previous studies, Tbx5 and GATA-4 were found to regulate the expression 
of a-MHC (Molkentin et al., 1994, Huang et al., 1995, Ching et al., 2005). Both 
transcription factors were also demonstrated to interact physically in 
co-immunoprecipitation assays and activate the ANP promoter cooperatively in 
trans-activation assays (Garg et al., 2003). In a latest follow-up study, heterozygous 
Tbx5/GATA-4 knockout mice demonstrated complete atrioventricular septal defects 
13 
and thin myocardium (Maitra et al., 2009). Cardiac gene expression analysis on the 
heterozygotes also revealed decreased mRNA level of a-MHC, a direct target of Tbx5 
and GATA-4 that has been implicated as a cause of human atrial septal defect 
(Molkentin et al., 1994，Huang et al., 1995, Ching et al., 2005). 
1.2.6 Serum Response Factor (SRF) 
SRF is the founding member of the MADS- box family of transcription factors 
(Molkentin and Markham, 1993, Zhang et al., 2002), similar to MEF2C discussed 
above. SRF binds to the consensus DNA sequences CC(A/T)6GG (also known as 
CArG box) located in the promoter regions of numerous cardiac, skeletal and smooth 
muscle expressed genes (Chin et al., 1998, Molkentin and Markham, 1993). In mice, 
SRF-deficient embryos exhibited impaired gastrulation and died before mesoderm 
formation, precluding elucidation of SRF function in specification and differentiation 
of muscle lineage (Arsenian et al., 1998). Using cardiac conditional gene targeted 
mice, SRF has been shown to be essential for heart development during 
embryogenesis, through regulating differentiation-specific genes involved in 
sarcomerogenesis and cell survival (Parlakian et al., 2004, Niu et al., 2005). 
SRF is a highly interactive transcription factor associated with a number of 
cardiac transcription factors. For instance, Nkx2.5 and GATA-4 have been reported to 
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be the co-regulators of SRF in the transcription of c-actin (Chen et al., 1996), 
a-actinin (Chen and Schwartz, 1996) and ANP (Durocher et al., 1996). Highly 
expressed in embryonic cardiac and smooth muscle lineages before postnatal 
dedication to form myocardium, myocardin was also identified as an extraordinarily 
potent SRF interacting partner that activates CArG box containing cardiac promoters 
such as that of ANP, MLC-2v and a-MHC and Nkx2.5 enhancer (Wang et al., 2001). 
1.2.7 Specificity Protein 1 (Spl) 
Spl is a transcription factor characterized by a series of three zinc fingers at the 
carboxyl terminus, by which it binds directly to consensus GC boxes (GGGCGG), GT 
motifs (GGGTGTGGC), or CT elements (CCTCCTCCTCCTCGGCCTCCTCCCC) 
to enhance transcription of many genes (Parakati and DiMario, 2005). GC boxes have 
been implicated in the regulation of cardiac promoters, but only little is known in the 
direct participation of Spl in cardiac development. A recent study has reported a 
positive regulatory role of Spl for the fibroblast growth factor receptor 1 (FGFRl) in 
neonatal cardiomyocytes by binding directly to the three identified Sp binding sites in 
the proximal promoter, which together contributed significantly to the proliferation, 
differentiation and maintenance of myocardium (Seyed and Dimario, 2007). 
Furthermore, functional analysis has suggested requirement of both Spl and GATA-4 
for optimal promoter activation of cTnl (Bhavsar et a l , 2000, Di Lisi et al., 1998). 
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Evidence supporting a role of Spl in cardiac muscle gene activation extended from a 
study which demonstrated the direct activation of the cardiac-specific cTnT promoter 
by Spl in primary cardiomyocyte culture (Azakie et al., 2006). Such cTnT promoter 
has also been shown to be regulated by other cardiac transcription factors such as 
MEF2C, GATA-4 and Nkx2.5. Therefore, Spl may act collaboratively with various 
cardiac transcription factors to activate the cTnT promoter for cardiac gene expression 
(Azakie et al., 2006). 
1.2.8 Activator Protein 1 (AP-1) 
AP-1 is a dimeric transcription factor composed of proteins belonging to the Fos, 
Jun or activating transcription factor (ATF) families. It binds to a palindromic DNA 
sequence TGAC/GTCA in the regulatory region of target genes (Karin et al., 1997). 
Mice lacking the AP-1 transcription factor c-Jun died at El3.0 but little is known in 
the exact cause of this embryonic lethality due to the diversified functions of AP-1 in 
development (Eferl et al., 1999). A detailed examination on hearts in the c-Jun 
knockout mice revealed a novel function of c-Jun in cardiac development, as the heart 
outflow tract of all fetuses showed malformation, which may be a contributing factor 
to their early lethality (Eferl et al., 1999). Consistently, several genes expressed in 
cardiomyocytes including ANP (Kovacic-Milivojevic and Gardner, 1993), BNP 
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(Grepin et al., 1994) and endothelin-1 (ET-1) (Kawana et al., 1995) contain AP-1 
elements in their promoters, suggesting a potential role of AP-1 in cardiac 
development. 
1.3 Reactive Oxygen Species (ROS) 
ROS refers to those oxygen-containing molecules that are highly unstable and 
highly interactive with other molecules. They are mostly derived from metabolism of 
molecular oxygen. Examples include superoxide anion (O2"), hydrogen peroxide 
(H2O2) and hydroxyl radical (OH ) (Fig. 5). 
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Fig. 5 A schematic diagram showing the formation of ROS. Adopted from Cell Signaling 
Biology (http://www.cellsignallingbiology. org/default.htm) 
17 
1.3.1 Cellular Production of ROS 
There are two main sites of cellular ROS production. One is at the level of 
plasma membrane, where the membrane-bound NADPH oxidase complex is activated 
during signal transduction; the other is at the mitochondrial respiratory chain, where a 
small percentage of total electrons are leaking that subsequently reduce molecular 
oxygen and generate ROS (Boveris and Chance, 1973, Giulivi et al., 1995, Han et al., 
2001) (Fig. 6). Further minor sources of ROS can be represented by cytochrome P450, 
xanthine oxidase, cyclooxygenase and lipoxygenase. 
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Fig.6 A schematic diagram showing the two main sites of ROS formation. Adopted from Cell 
Signaling Biology (http://www.cellsignallingbiology. org/default. htm) 
1.3.2 Maintenance of Redox Balance 
Maintaining intracellular redox balance is very important for normal cellular 
functions, as an excessive and deliberate production of ROS would lead to cellular 
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destruction like oxidation of proteins and lipids as well as induction of DNA damage. 
In this regard, cells must possess certain defense mechanism for protection. 
Superoxide dismutase, glutathione peroxidase and catalase are three well-known 
anti-oxidant enzymes that help eliminate excessive ROS. Apart from these enzymes, 
all cells contain a variety of reducing substances, e.g. glutathione (GSH), thioredoxin, 
glutaredoxin, thiols, ubiquinone and vitamins A, C, E which efficiently scavenge 
ROS. 
1.3.3 Redox Signaling 
Being rapidly generated, highly diffusible, easily degraded and ubiquitously 
present in all cell types, ROS ideally fulfill the prerequisites as intracellular signaling 
molecules. During the past decade, ROS have been demonstrated to be important 
mediators in the regulation of many signal transduction pathways involved in cell 
proliferation and differentiation (Burdon, 1996，Sauer et al., 2001). Exogenous 
addition of ROS at low concentrations has been shown to promote proliferation of 
various cell types including fibroblasts (Burdon, 1995), amnion cells (Ikebuchi et al., 
1991), smooth muscle cells (Rao and Berk, 1992) and aortic endothelial cells 
(Ruiz-Gines et al., 2000). Stimulatory effect of ROS on cell differentiation is also 
clearly illustrated in the differentiation of erythrocytes (Chenais et al., 2000), 
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monocytes (Yang and Shaio, 1994), neurons (Katoh et al., 1999) as well as osteoclasts 
(Steinbeck et al., 1998). In contrast, external addition of anti-oxidants or 
over-expression of anti-oxidant enzymes has been found to inhibit cell proliferation 
(Brown et al., 1999, Zhong et al., 1996). These observations support the notion that 
ROS can act as "second messenger" and modulate various signaling cascades for 
growth and development. 
1.4 Nitric Oxide (NO) and NO Signaling 
NO is a free radical recognized to have very important physiological roles. Its 
synthesis is carried out by nitric oxide synthase (NOS), which consists of three 
different isoforms: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial 
NOS (eNOS). These enzymes share a similar mechanism of NO production, which 
use L-arginine, oxygen and NADPH as the main substrates. The regulation on NOS is 
different among the three isoforms, as they are located differently in cell 
compartments. 
The action of NO is complicated, since its mode of signal transmission can be 
markedly different. For examples, NO can initiate its biological effects through 
directly modulating the functions of transition metal-containing enzymes and 
transcription factors such as cyclooxygenase 2 (COX-2) (Goodwin et al., 1998, 
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Gunther et al., 1997) and the vitamin D receptor-retinoid X receptor heterodimers 
(Kroncke and Carlberg, 2000). However, the main action of NO is mediated through 
the cyclic GMP (cGMP) signaling pathway (Murad, 1994, Murad et al., 1993, Murad, 
1986), where it stimulates the soluble guanylyl cyclase (sGC) to produce cGMP that 
activates ion channels, protein kinases, phosphatases and phosphodiesterases (Lucas 
et al., 2000). Such diverse actions of NO evident its importance in life processes. 
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1.5 Aims of the Study 
The hypothesis of this project is ROS, by acting as a signaling molecule, mediates 
the differentiation of mouse ES cells into cardiac lineage. Therefore, this project was 
carried out to investigate the role of ROS in the differentiation of mouse ES cells into 
cardiomyocytes. The specific aims of this project were: 
1) to assess the level of endogenous ROS during cardiac differentiation; 
2) to investigate the effect of exogenous addition of NO and H2O2 on cardiac 
differentiation; and 
3) to examine the in vitro mechanism of exogenous ROS on cardiac differentiation. 
One of the problems currently encountered for the development of ES cells-based 
transplantation therapy lies in the low yield of cardiomyocytes derived from ES cells 
as mentioned previously. Understanding the role of ROS as key mediators in 
signaling cascades for cardiac differentiation of mouse ES cells may provide hints 
for pharmacological intervention, which in turn may aid to increase the yield of 
ES-cell derived cardiomyocytes. 
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CHAPTER TWO MATERIALS AND METHODS 
2.1 Mouse Embryonic Fibroblast (MEF) Culture 
2.1.1 Derivation of MEF 
Used as feeder cells for mouse ES cell culture, MEF was isolated from mouse 
embryos of CD-I strain at 13-14 days of gestation. To start the isolation process, mice 
were neck-dislodged, sterilized with alcohol and placed in a sterile primary culture 
hood for dissection. Using sterilized instruments, the abdominal skin was firstly cut 
open, followed by the peritoneum to expose the uterine horns. The whole uterine horn 
was removed and washed three times with 10ml PBS in a sterile Petri dish. Then, 
embryonic sacs were cut open to release embryos, which were subsequently 
transferred to a new dish and washed three times with 10ml PBS. Counting and 
recording the number of embryos obtained, visceral tissue which looked darker in 
color was carefully removed from the embryos one by one. After three successive 
washes with PBS, the cleared embryos were then minced for approximately 5 - 1 0 
minutes into grain-sized pieces. To have better cell dissociation, 2ml trypsin was 
added and the tissue minced for additional few minutes. Afterwards, another 5 ml 
trypsin was added to the minced tissue, pipetted up-and-down vigorously and placed 
0 
in a 37 C incubator for 30 minutes. 
After 30-minute incubation, dissociated cells were pipetted again until a sludgy 
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consistency was obtained. MEF culture medium containing Dulbecco's modified 
Eagle's minimal essential medium (DMEM; Hyclone), supplemented with 10% 
heat-inactivated (57°C, 30 minutes) fetal bovine serum (FBS; Hyclone), 2 mM 
L-glutamine (Gibco), 1 % (v/v) non-essential amino acid solution (NEAA; Gibco) and 
1% (v/v) penicillin / streptomycin solution (PS; Gibco), was next added and the cell 
0 
suspension was distributed into several T75 culture flasks and incubated at 37 C 
overnight. The number of T75 flasks required equals to the number of embryos 
recovered divided by three. 
Primary MEF cultures were observed under microscope the next day to 
determine the confluency of cell layer. Cells were harvested when the flasks were 
over 90% confluent. For stock keeping, cells were frozen in 10% DMSO/ MEF 
0 
medium at -80 C overnight and transferred to liquid nitrogen for long term storage. 
2.1.2 Maintenance of MEF Culture 
To start maintaining the MEF culture, a frozen stock vial of Passage-zero MEF 
was firstly thawed from liquid nitrogen. It was briefly rolled between hands to remove 
� 0 
surface frost, and then immersed in a 37 C water bath with gentle swirl until a small 
ice crystal remained. The vial was slightly sterilized with ethanol spray and cells 
within it were transferred to a 50ml falcon. To avoid osmotic shock, 9 ml MEF culture 
24 
medium was next added drop-wise to cells. The cell suspension was then centrifuged 
0 
at 1000 rpm, 4 C for 5 minutes for the removal of cryoprotectant from cell culture. 
Upon aspirating the supernatant, the cell pellet was reconstituted in 10 ml MEF 
0 
culture medium, transferred to T75 flask and incubated at 37 C with 5% CO^ supply. 
Cell density was monitored daily and cells were passed at 1:3 or 1:4 ratio weekly to 
passage four. 
2.1.3 Irradiation of MEF 
To harvest cells for irradiation, medium was firstly aspirated from the flask and 
the cell monolayer washed with 5ml PBS. For cell dislodgement, 4ml trypsin was 
0 
added into the flask, accompanied by 3-5 minute incubation at 37 C. When cells had 
completely dislodged, 5 ml MEF culture medium was added to inhibit trypsin reaction 
and the whole cell suspension was transferred to a 50ml falcon. Upon a brief 
0 
centrifugation at 1000 rpm, 4 C for 5 minutes, supernatant was replaced with fresh 
medium and the cell suspension was thoroughly pipetted. Number of cells was next 
counted, and the amount required for seeding on plates was made up to 20 ml cell 
suspension, subjected to gamma irradiation at 7000-8000 rads. Irradiated cell 
0 
suspension was immediately kept in ice, followed by centrifugation at 1000 rpm, 4 C 
for 5 minutes. The cell pellet was resuspended at around a million cells per ml in MEF 
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culture medium. Cell number was counted again and cell suspension was further 
5 
diluted to required concentration, i.e. 1.4 X 10 cells per ml. 2 ml of the diluted cell 
suspension was finally placed on gelatin-coated 6-well dishes and incubated overnight 
0 
in incubator at 37 C with 5% CO^ supply, ready to be used as feeder cells for ES cell 
culture. 
2.2 Mouse ES Cell Culture 
2.2.1 Maintenance of Undifferentiated Mouse ES Cell Culture 
Similar to MEF culture, a frozen vial of mouse ES cells (line D3) was firstly 
thawed from liquid nitrogen. They were then cultivated in undifferentiated state on 
mitotically inactivated feeder layers of primary MEF in DMEM (Hyclone), 
supplemented with 15% heat-inactivated (57°C, 30 minutes) FBS (Hyclone), 0.1 mM 
p-mercaptoethanol (Sigma), 2 mM L-glutamine (Gibco), 1% (v/v) NEAA (Gibco), 
1% (v/v) PS (Gibco) and 1000 U/mL recombinant mouse leukemia inhibitory factor 
(LIF; Chemicon) in a humidified 5% CO2 incubator at 37°C. The mouse ES cell 
culture was split every 2 days in 1:10 ratio and the culture medium refreshed daily. 
2.2.2 Differentiation of Mouse ES Cells 
To induce differentiation of mouse ES cells, culture medium was firstly aspirated 
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and the adherent ES cells were washed once with PBS. Cells were then enzymatically 
dissociated with 0.05% trypsin-EDTA (Gibco) and seeded on gelatin-coated Petri dish 
for 30 minutes for removal of feeder cells. Differentiating ES culture was established 
by formation of embryoid bodies (EBs) in hanging drops with differentiation medium, 
which was identical to the undifferentiated mouse ES cell medium but without LIF. 
Hanging drops (20p_l) containing about 800 ES cells each were placed on the lids of 
Petri dishes filled with PBS and were cultivated for 2 days and another 5 days in Petri 
dishes. On day 7 post-differentiation, EBs were plated onto gelatin-coated culture 
plates. Rhythmically beating EB outgrowth representing spontaneously beating 
cardiomyocytes was defined as the phenotypic landmark of successful differentiation. 
2.2.3 Exogenous addition of hydrogen peroxide (H2O2) and NO 
H2O2 and NO were both exogenously added to the mouse ES cell culture during 
differentiation. Similar to general differentiation process, differentiating ES culture 
was established by formation of EBs in hanging drops at day 0. Once the EBs were 
cultivated and kept in suspension at day 2, different concentrations of H2O2 (AnalaR) 
or NO by sodium nitroprusside (SNP; Sigma) were added to the differentiation 
medium consecutively for 5 days. On day 7 post-differentiation, EBs were again 
plated onto gelatin-coated culture plates and screened for spontaneously beating 
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cardiomyocytes from the next day onwards. 
2.3 ROS Localization Study 
2.3.1 Frozen Sectioning 
Both 3-day-old and 7-day-old EBs to be frozen sectioned were firstly washed 
once with PBS, and then transferred directly to the cryomolds. Each cryomold was 
slowly and carefully filled to the top with OCT compound (Sakura). It was important 
to ensure that the EBs had been fully submerged in the media without formation of air 
bubbles. Next, each cryomold was snap frozen in liquid nitrogen for hardening of the 
OCT compound. The tissue embedded blocks were then subject to frozen section or 
placed at -80°C freezer for storage. 
2.3.2 Confocal microscopy for ROS detection 
Frozen sections (20|_im thick) of 3-day-old and 7-day-old EBs weie mounted on 
glass slides, air-dried for 1 hour and washed three times with PBS for removal of 
residual OCT. Sections were then stained with 5|iM dihydroethidium (DHE; Sigma), a 
superoxide indicator which gives a red fluorescence upon oxidation, for 30 minutes at 
room temperature in darkness. Confocal images were obtained using a Fluoview 
FVIOOO laser scanning confocal system (Olympus America Inc.) 
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2.4 Intracellular ROS Measurement 
2.4.1 Chemistry of 2',7'-dichlorodihydrofluorescein diacetate ( H 2 D C F D A ) 
H2DCFDA is a non-polar compound capable of entering the cells, where cellular 
esterases readily hydrolyze its acetyl moieties to produce non-fluorescent intermediate 
H2DCF. In the presence of intracellular ROS, H2DCF is rapidly oxidized to yield a 
highly fluorescent product (DCF). An accumulation of fluorescence therefore 
indicates the endogenous production of ROS. 
2.4.2 Flow Cytometry for ROS Measurement 
EBs at different differentiation stages were harvested, washed once with PBS and 
dissociated with 0.05% trypsin-EDTA for 5 minutes at 37�C, then were pipetted 
up-and-down for several times to generate a single cell suspension. The experiment 
was performed at the condition of cell viability more than 80%. Single cells were 
incubated with 20}iM H2DCFDA (Sigma) for 30 minutes. The fluorescence intensity 
of cells was then assayed in a flow cytometer (FACSCanto, Becton Dickinson). Each 
plot represents 10,000 viable cells (non-viable cells were excluded by appropriate 
gating). 
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2.5 Gene Expression Study 
2.5.1 Primer Design 
Primers for real-time PCR were designed using Primer Express 3.0 (Applied 
Biosystems), which flanked 100-300 base pairs of the target gene sequence with an 
0 
annealing temperature of 58-60 C. The sequences of the qPCR primers used in this 
study were listed in the following tables: 
Table 1 Primer sequence of cardiac transcription factors for real-time PCR 
Gene Primer sequence Product size (bp) 
GATA-4 Forward: 5' TGAAGAGATGCGCCCCATCAA 3' 151 
Reverse: 5' ATAGCCTTGTGGGGACAGCT 3' 
Nkx2.5 Forward:5' CCCACTTTATTGACGTAGCC 3, 157 
Reverse: 5' AAAAACATAAATACGGGTGG 3' 
MEF2C Forward: 5' CCCCTTCGAGATACCCACAA 3' 151 
Reverse: 5' GAAGGTCTGGTGAGTCCAATG 3' 
HANDl Forward: 5' CAAACGAAAAGGCTCAGGAC 3’ 150 
Reverse: 5' ATGTAACTGGTAGCCAGGCG 3' 
HAND2 Forward: 5' GCAGGACTCAGAGCATCAAC 3, 126 
Reverse: 5' TGAGGTAGGCGATGTAGCTG 3, 
Sp-1 Forward: 5‘AGGCTGCCCATTTGTACTCATTTA3‘ 100 
Reverse: 5’GCCTGTTAGGAGGTCCCTGAA3’ 
Tbx5 Forward: 5'AGCACTTCTCCGCTCATTTCAC3' 110 
Reverse: 5,TGAGGTCTGGTGCTGAAACATC3, 
API Forward: 5‘CGGACTCCGGACTGTTCATC3‘ 100 
Reverse: 5‘CTCCAAATGCTCCCCAAAATAC3^ 
SRF Forward: 5' TGTGCCACAGTATGGTCGTT 3’ 120 
Reverse: 5’ CTCTGACCCCCATTCCTGTA 3’ 
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Table 2 Primer sequence of cardiac-specific markers for real-time PGR 
Gene Primer sequence Product size (bp) 
a-actinin Forward: 5' ACTACCACGCAGCGAACC 3' 277 
Reverse: 5' TCCCCTGAAATGACCTCC 3' 
a-MHC Forward:5' AGCTGACAGGGGCCATCAT3' 
Reverse: 5' ACATACTCGTTCCCCACCTTC 3' 
cTnT Forward:5' TTCATGCCCAACTTGGTGCC 3' ^ 
Reverse: 5' CTCTCTTCAGCCAGGCGGTTC3' 
c-actin Forward:5' CCAGCCCAGCTGAATCC 3' 106 
Reverse: 5' CCATTGTCACACACCAAAGC 3' 
2.5.2 RNA Extraction 
Cells were harvested, washed once with PBS and lysed directly in TRIzol 
reagent (Invitrogen). The cell lysates were passed through a 21-G needle on a 1 mL 
syringe several times and incubated at room temperature for 5 minutes for complete 
dissociation of nucleoprotein complexes. With the addition of chloroform, the tubes 
containing cell lysates were vigorously shaken for 15 seconds and incubated at room 
temperature for another 3 minutes, before subjected to centrifugation at 12,000g foi-
l s minutes at 4'^ C. Following centrifugation, the upper aqueous phase was transferred 
to a new tube and the RNA within it was precipitated with isopropanol. Incubating the 
samples at room temperature for 10 minutes and centrifuging at 12,000g for 10 
minutes at 4°C, a gel-like RNA pellet was obtained. The RNA pellet was then washed 
with 75% ethanol, centrifuged at 7,500g for 15 minutes at 代，air dried for 5-10 
minutes and finally dissolved in RNase-free water. 
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2.5.3 DNase Treatment 
Prior to reverse transcription, raw RNA was treated with deoxyribonuclease I 
(DNase I, Invitrogen) for elimination of genomic DNA. In brief, raw RNA was 
incubated with DNase I in reaction buffer for 15 minutes at room temperature. The 
enzyme was then inactivated by the addition of EDTA solution and incubation for 10 
minutes at 65°C. RNA concentration was determined with the Nanodrop 
Spectrophotometer. 
2.5.4 Reverse Transcription 
First strand cDNA were synthesized from DNase I-treated RNA samples using 
the superscript™ III First-Strand Synthesis Kit (Invitrogen). cDNA synthesis was 
performed in the first step by incubating the RNA samples with oligo(dT)2o and dNTP 
mix at 65°C for 5 minutes. RNA samples were then incubated with cDNA synthesis 
mix containing reaction buffer, magnesium chloride (MgCh), dithiothreitol (DTT), 
RNase OUT^m and SuperScript ™ III reverse transcriptase at 50°C for 50 minutes. 
Reactions were terminated upon heating at 85°C for 5 minutes. Chilled on ice, 
RNaseH was added to each tube and incubated further at 37°C for 20 minutes. 
Synthesized cDNA were placed at -20°C freezer for storage. 
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2.5.5 Quantitative Real Time PCR 
Levels of mRNA expression of target genes were measured with the method of 
quantitative real-time PCR. Power SYBR Green PCR Master Mix (Applied 
Biosystem), which was a convenient premix of all the components, except primers, 
template and water necessary to perform real-time PCR using SYBR Green I Dye was 
employed. Binding to double-stranded DNA, SYBR Green exhibited green 
fluorescence, which could be monitored in real time. By measuring the proportional 
increase in fluorescence intensity due to formation of DNA-dye-DNA complex, an 
amplification plot was obtained. Threshold cycles were then directly determined for 
subsequent calculation of gene expression level among different samples. 
Real-time PCR was performed in triplicate in a 20 |il reaction mixture on a 
96-well PCR plate following manufacturer's suggestion. (3-actin was included as the 
endogenous control for all target genes in each trial. Reaction was performed in the 
0 
ABI Fast 7500 real-time PCR machine with standard profile: 1 cycle of 50 C for 2 
0 0 0 
minutes, 95 C for 10 minutes, 40 cycles of 95 C for 15 seconds, 60 C for 1 minute. 
Levels of gene expression were quantified using the Fast SDS program with auto-Ct 
settings. The threshold cycle number (Q) value defines the number of cycles for 
which the SYBR Green signal generated was high enough to be detected and this Q 
values should fall in the log phase of PCR amplification. Normalized the results with 
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the endogenous control, the AA Ct value for each gene was determined with reference 
to the control sample. 
2.5.6 Quantification of mRNA Expression 
Upon completion of real-time PGR, the threshold for various gene expressions 
were checked to ensure they were in the log phase of PGR amplification. To quantify 
the mRNA expression of each gene, Ct for housekeeping gene expression was firstly 
subtracted from Q of target gene to obtain ACt. Then AQ of control sample was then 
subtracted from ACt of experimental sample to obtain AACt. Fold change was finally 
determined with the formulae While AACt of control sample should be equal to 
0’ fold change of control should be equal to 1. 
2.6 Protein Expression Study 
2.6.1 Total Protein Extraction 
Whole cell lysates were prepared from untreated and H^Os-treated EB outgrowth 
of differentiation day 7+25 depending on experimental purposes. In brief, cells were 
harvested, washed with PBS once and lysed in ice-cold RIPA buffer containing 50mM 
Tris-HCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1% protease inhibitor 
cocktail (Roche) and 1% phosphatase inhibitor cocktail (Roche). The cell lysates were 
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incubated on ice for 10 minutes, passed through a 21-G needle on a 1 mL syringe 
several times and centrifuged at 16,000g for 20 minutes at 4°C. The supernatant was 
collected and the protein concentration was estimated by Bradford assay (Bio-Rad 
Laboratories). 
2.6.2 Nuclear and Cytosolic Protein Extraction 
Cytoplasmic and nuclei protein lysates were prepared from untreated and 
H202-treated EBs of Day 3 to Day 7. In brief, cells were harvested, washed with PBS 
once and lysed in ice-cold fractionation buffer containing lOmM Tris-HCl, 0.5% 
NP-40, lOmM NaCl and 3mM MgCh, freshly supplemented with protease inhibitor 
cocktail [Leupeptin (l)ig/ml), Aprotinin (5|ig/ml), PMSF (100|_ig/ml), sodium 
orthovanadate (100|ag/ml), EGTA (200昭/ml) and EDTA (200|ig/ml)], and 
phosphatase inhibitor cocktail [NaF (250mM), p-glycerolphosphate (500mg/ml) and 
HEPES (50mM, pH7.3)]. Cell lysates were vortexed, incubated on ice for 10 minutes 
and centrifuged at 500g for 10 minutes at The supernatant obtained was further 
centrifuged to spin down any remaining impurities at 13,000g for 10 minutes at 4®C 
for the collection of 'cytoplasmic fraction'. The pellet was washed three times with 
washing buffer (lOmM Tris-HCl, sucrose solution, MgCl2) accompanied by 
centrifugation at 500g for 5 minutes at 4 °C. Centrifuged at 7,500g after the last wash 
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to exclude any remaining cytosolic components, the pellet was resuspended with 
resuspension buffer containing 20mM Tris (pH 8.0) and 2% SDS, freshly 
supplemented with protease and phosphatase inhibitor cocktail. Protein concentration 
was estimated by Bradford assay (Bio-Rad Laboratories). 
2.6.3 Measurement of Protein Concentration 
To determine the protein concentration, Bradford reagent was mixed with each 
sample in a flat bottom 96-well plate in duplicate. Bovine serum albumin (BSA) 
standards of various concentrations were also included. Incubated for 5 minutes at 
room temperature, the absorbance at wavelength 595 nm of each well was measured 
by a microplate reader (Model 3550, BIO-RAD). Protein concentration of each 
sample was then determined directly from the BSA standard curve. 
2.6.4 De-sumolyation Assay 
Whole cell lysates were prepared from untreated and H202-treated EBs of 
differentiation day 4 and day 7. Harvested cells were washed with PBS once and lysed 
in ice-cold fractionation buffer containing 50mM Tris-HCl, 1% NP-40, 1% sodium 
deoxycholate and 0.1% SDS, freshly supplemented with protease inhibitor cocktail 
[Leupeptin (1 ^ig/ml), Aprotinin (5|ig/ml)，PMSF (100|ag/ml), sodium orthovanadate 
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(100|ig/ml), EGTA (200|ig/ml) and EDTA (200|^g/ml)], as well as phosphatase 
inhibitor cocktail [NaF (250mM), P-glycerolphosphate (500mg/ml) and HEPES 
(50mM, pH7.3)]. The cell lysates were incubated on ice for 10 minutes and 
centrifuged at 16,000g for 20 minutes at 4°C. The supernatant was collected and the 
protein concentration was estimated by Bradford assay. Protein lysates (30|j.g) were 
directly treated with 300ng of SUMO-specific protease 1 (SENP 1) and 300ng of 
SUMO-specific protease 2 (SENP 2) at 37°C for 30 minutes. Samples were then 
subjected to electrophoresis and analyzed by Western blot as described in section 
2.6.7. 
2.6.5 De-phosphorylation Assay 
Whole cell lysates were prepared from untreated and H202-treated EBs of 
differentiation day 4 and day 7. Similar to total protein extraction except without 
phosphatase inhibitor treatment, harvested cells were washed with PBS once and 
lysed in ice-cold fractionation buffer containing lOmM Tris-HCl, 0.5% NP-40, lOmM 
NaCl and 3mM MgCh, freshly supplemented with protease inhibitor cocktail 
[Leupeptin (l|ig/ml), Aprotinin (5|ig/ml), PMSF (100昭/ml) and EGTA (200|ig/ml)]. 
The cell lysates were incubated on ice for 10 minutes and centrifuged at 16，000g for 
20 minutes at 4"C. The supernatant was collected and the protein concentration was 
37 
estimated by Bradford assay. Aliquots of protein lysate (30|ig) were treated with 30 
units of alkaline phosphatase from calf intestine (10,000 U/ml, New England Biolabs) 
at 37°C for 30 minutes. Samples were then subjected to electrophoresis and analyzed 
by Western blot as described in section 2.6.7. 
2.6.6 De-glycosylation Assay 
Whole cell lysates were prepared from untreated and HaOs-treated EBs of 
differentiation day 4 and day 7. Similar to total protein extraction, harvested cells 
were washed with PBS once and lysed in ice-cold fractionation buffer containing 
lOmM Tris-HCl, 0.5% NP-40, lOmM NaCl and 3niM MgCb, freshly supplemented 
with protease inhibitor cocktail [Leupeptin (l|ig/ml), Aprotinin (5|ig/ml), sodium 
orthovanadate (100|ig/ml), EGTA (200|ig/ml) and EDTA (200|ig/ml)], and 
phosphatase inhibitor cocktail [NaF (250mM), p-glycerolphosphate (500mg/ml) and 
HEPES (50mM, pH7.3)]. The cell lysates were incubated on ice for 10 minutes and 
centrifuged at 16，000g for 20 minutes at 4 � C . The supernatant was collected and the 
protein concentration was estimated by Bradford assay. Protein lysates (30|j.g) were 
denatured in lOx Glycoprotein Denaturing Buffer (New England Biolabs) at 100°C 
for 10 minutes. Denatured samples were then treated with PNGase F (New England 
Biolabs) in lOx G7 Reaction Buffer and 10% NP40 and incubated at 37°C for 45 
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minutes. Samples were then subjected to electrophoresis and analyzed by Western 
blot as described below. 
2.6.7 Western Blot 
Aliquots of lOOfig total protein or 20^g nuclear/cytosolic protein were mixed in 
1:1 ratio with 2x sample loading buffer containing 125mM Tris-HCl (pH 6.8), 4% 
sodium dodecyl sulfate (SDS), 20% glycerol, 0.06% bromophenol blue and 10% 
P-mercaptoethanol. Depending on the molecular weight of target protein, samples 
were separated in 7.5 - 12.5% SDS polyacrylamide gel. Pre-stained Novex Sharp 
Standard marker (Invitrogen) was loaded in parallel as a standard molecular weight 
marker. The 4% stacking gel was electrophoresed at 50 volts for 45 minutes while the 
separating gel was increased to 100 volts for 1.5-2 hours. After electrophoresis, the 
gel was electrophoretically transferred onto PVDF membranes (Millipore) with a 
Trans-blot SD wet transfer tetra-cell (Bio-Rad) at 100 volts for 1-3 hours, duration of 
which depended on the size of target protein. Membranes were blocked for 1 -2 hours 
at room temperature with 5% dried non-fat milk in Tris-buffered saline containing 
0.1% Tween-20 (TBST). Incubation with primary antibodies (Tables 4-6) was carried 
out at 4"C overnight. After primary antibody probing, membranes were subjected to 
three successive washes in TBST, each for 10 minutes with gentle shaking. 
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Membranes were next incubated with HRP-conjugated secondary antibody (DAKO) 
in the dilution of 1:5,000 for 45 minutes at room temperature, followed by three 
successive 15-minute washes. Protein expression was detected by enhanced 
chemiluminescent substrate (ECL; Pierce) and protein bands visualized by film 
exposure, p-actin or p-tubulin was used as an internal control. The density of the 
products was quantified using AlphaEaseFC software (Alpha Innotech). 
Table 3 Antibodies against cardiac-specific structural protein: 
Cardiac protein Antibody dilution Expected size Company 
a-actinin 1:1,000 100 kPa Sigma 
a-MHC 1:500 223 kPa Abeam 
cTnT 1:1,000 35 kPa Abeam 
c-actin 1:1,000 45 kDa Abeam 
Table 4 Antibodies against cardiac-specific transcription factors: 
Cardiac protein Antibody dilution Expected size Company 
GATA-4 1:500 48 kDa Santa Cruz 
MEF2C 1:500 48 kDa Aviva Systems Biology 
AP-1 1:500 30 kDa Santa Cruz 
^ 1:500 65 kDa Santa Cruz 
1:1000 90 kDa Santa Cruz 
HANDl 1:500 24 kDa Abeam 
Table 5 Antibodies against housekeeping protein: 
Cardiac protein Antibody dilution Expected size Company 
P-actin 1:3,000 45 kDa Abeam 
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P-tubulin 1:1,000 55 kPa Santa Cruz 
TBP 1:2,000 38kDa Abeam 
2.7 Statistical Analysis 
Data were given as mean values +/- S.E.M., with n denoting the number of 
independent experiments. Statistical analysis was performed by adjusted student t 
tests. A value of 户<0.05 was considered to be statistically significant. 
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CHAPTER THREE RESULTS 
Difference in levels and distribution of endogenous ROS during cardiac 
differentiation 
Our data showed that differentiating EBs endogenously generated ROS, which 
may be involved in the differentiation of mouse ES cells into cardiomyocytes. From 
confocal microscopic analysis, distribution of endogenous ROS was found to vary 
with post-differentiation time. Three-day-old EBs had a higher level of ROS and its 
distribution was uniform, spreading across the whole EB section. In contrast, 
seven-day-old EBs had a lower level of ROS and its distribution mainly concentrated 
at the centre of the EB section (Fig. 7). 
Consistently, flow cytometric analysis demonstrated that the level of endogenous 
ROS changed during the course of differentiation, as indicated by the percentage of 
DCF-positive cells (Fig. 8). ROS levels remained elevated from undifferentiated state 
(46.40% 士 0.79%) to differentiation Day 1 (69.67% 土 7.29o/o) until Day 3 (82.33% 土 
1.39%), but reduced gradually from Day 4 (75.90% 士 8.25o/o) to Day 7 (27.10% 士 
13.11%) {Fig.9). 
Stimulation of ES cell-derived cardiomyocyte differentiation by H2O2 
To study the role of ROS on cardiac differentiation, we incubated EBs with 
different concentrations of NO or H2O2 consecutively for 5 days (Day 2 - Day 7 of 
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differentiation), and evaluated its effect by determining spontaneous beating activity 
of EBs starting from day one after plating (i.e. Day 7+1). Exogenous application of 
NO by SNP at low concentration (InM - lOOnM) to the differentiating EBs brought 
no prominent effect on the spontaneous beating activity (Fig. 10). Interestingly, at high 
concentration of SNP (10|iM), there was even a suppressive effect on differentiating 
ES culture towards cardiac differentiation. 
In contrast, the treatment of differentiating EBs with H2O2 significantly increased 
the percentage of spontaneous beating EB during the early phase of differentiation 
{Fig. 11). The most prominent effect was observed when treating differentiating EBs 
with 10|iM H2O2, with an approximate increase of 10%, 50% and 70% of 
spontaneously beating EBs on Day 2, Day 3 and Day 4 respectively, as compared to 
the untreated control. Both lOOnM and InM H2O2 also showed an enhancement of 
cardiac differentiation during the initial phase of differentiation, though to a lesser 
extent than 10|iM H2O2. A trend of increase in mRNA expression of several 
cardiac-specific markers was observed {Fig. 12). Furthermore, treatment of EBs with 
H2O2 significantly increased the protein expression of cardiac-specific markers (a) 
a-MHC, (b) C-actin, (c) a-actinin and (d) cTnT {Fig. 13), which clearly demonstrated 
stimulation of cardiomyogenesis of ES cells by exogenous addition of H2O2. 
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H202-treatment induced expression of cardiac transcription factors 
To further elucidate the role of ROS in cardiac differentiation, the effect of 
exogenous H2O2 on the expression of cardiac transcription factors was assessed. 
Among the nine transcription factors studied, H202-treatment displayed no observable 
effect on the mRNA expression of HAND2 {Fig. 14b) and Tbx5 (Fig. I4g). As for the 
mRNA expression of AP-1 {Fig. 14a), MEF2C (Fig.Md), Spl (Fig.Ue) and SRF 
{Fig. 14f), addition of H2O2 resulted in a remarkable increase on day 4 but decrease on 
day 7. A reverse effect was observed for HANDl (Fig. 14c)-, H2O2 treatment resulted 
in a down-regulation of HANDl on day 4 but an up-regulation of HAND 1 on day 7. 
Subsequently, H2O2 administration led to up-regulation of GATA-4 {Fig.l4h) 
expression on day 4 and down-regulation ofNkx2.5 {Fig.I4i) expression on day 7. 
Western blot was also performed to investigate the protein expression of various 
cardiac transcription factors upon HbOs-treatment. Western blot of GATA-4, MEF2C, 
Spl yielded specific bands at expected sizes according to literature. In contrast, 
western blot of AP-1 and SRF yielded multiple bands {Fig. 15); yet, pre-incubation of 
AP-1 and SRF antibodies with their respective peptides revealed the location of 
specific bands (Fig. 15). For instance, incubation of SRF antibody with specific 
peptides revealed disappearance of two bands of desirable sizes {Fig. 15b). It is 
speculated from previous work by Kemp and Metcalfe that these two bands 
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corresponded to the SRF isoforms SRF-L and SRF-M respectively (Kemp and 
Metcalfe, 2000). 
In consistence, the protein expression of various transcription factors upon 
H202-treatment displayed similar profiles to their corresponding mRNA expression 
profiles. Exogenous H2O2 addition resulted in prominent up-regulation of AP-1 
(Fig�6a), GATA-4 {Fig.l6b\ MEF2C {Fig.l6c\ SRF (both SRF-L and SRF-M) 
(Fig.ldd) and Spl (Fig.lde) on day 4. While on day 7, HaOi-treatment showed 
distinctive effects on the expression of various transcription factors in protein level. 
As compared to the untreated control, expression of AP-1 (Fig. J 6a)’ SRF-M (Fig. 16d) 
and Spl (Fig.Ide) remained more or less similar on day 7. On the one hand, an 
elevation in protein expression of GATA-4 {Fig. 16b) was observed, whereas a 
reduction in MEF2C {Fig. 16c) and SRF-L {Fig.l6d) expression was found. These 
results suggested a potential role of ROS in mediating the differentiation of mouse ES 
cells into cardiac lineage. 
In addition to the possible post-translational modifications of cardiac 
transcription factors, preliminary data from de-phosphorylation {Fig. 17a-e), 
de-sumoylation (Fig. 18a-e) as well as de-glycosylation (Fig.l9a-e) assays showed 
that the cardiac transcription factors studied may not be modified post-translationally 
in both control and H^Oi-treated samples on day 4 and day 7. Translocation studies 
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have also been carried out on the transcription factors Nkx2.5 and GATA-4, using 
H202-treated samples from day 3 to day 7. Preliminarily, H2O2 administration 
exhibited no observable effect on the translocation of Nkx2.5 (Fig. 20a-e), while 
apparently promoted the nuclear translocation of GATA-4 (Fig.21a-e) on day 3 during 
differentiation. 
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3.1 Study of Endogenous ROS 
3.1.1 Level and Distribution of Endogenous ROS 
Bright view Fluorescent view 
麗 瞎 
幽 
Fig. 7: Results of confocal microscopy. Different level and distribution of endogenous 
ROS could be observed when compared 3-day-old and 7-day-old EBs. 
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3.1.2 Quantification of Intracellular ROS 
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Fig. 8: Typical FACS profiles of cells stained with H2DCFDA on (a) undifferentiated 
ES cells; and differentiated EBs on (b) Day 1; (c) Day 2; (d) Day 3; (e) Day 4; ( f ) Day 
5; (g) Day 6 and (h) Day 7. The x-axis corresponded to the fluorescence intensity and 




8 0 - * ^ ^ T T 
s 70 - i H B B H 
，I i i m i I i 
J m m m m m m m m 
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(b) 
Samples Percentage of H2DCFDA -positive cells (%) 
Undifferentiated ES cells 46.40 士 0.79 
Day 1 EB 69.67 ± 7.29 
Day 2 EB 71.97 士 4.02* 
Day 3 EB 82.33 士 1.39*** 
Day 4 EB 75.90 ± 8.25 
Day 5 EB 70.97± 11.10 
Day 6 EB 46.23 ± 15.21 
Day 7 EB 27.10 士 13.11 
Fig. 9(a)(b): Summarized results of flow cytometric analysis. The level of endogenous 
ROS was changing during the initial course of differentiation, with a peak of ROS 
production at Day 3 to 4. (Results: Mean 士 SEM, n=3) *P<0.05 and 彻P<0.001’ 
significantly different to undifferentiated ES cells. 
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3.2 Effect of Exogenous Addition of Nitric Oxide (NO) on Cardiac Differentiation 
3.2.1 Beating Profile of NO-treated EBs 
• Control 
1叨~] —A— lO^iMSNP 
e � T ^ 營 I H T lOOnMSNP 
I 即 - / Y \ InMSNP 
f . T/7： I r m ^ i: 
O f ^^ ~ I 1 1 1 1 1 1 
0 2 4 6 8 10 12 14 16 
Days of differentiation "7+x" 
Fig. 10: A beating profile of control and NO-treated samples. EBs were treated with 3 
different concentrations (InM，lOOnM and lOjuM) of SNR Percentage of beating EBs 
was monitored from day 7+1 to day 7+15. As compared to the control, an exogenous 
addition of SNP led to a delay in the appearance of as well as a decrease in the 
percentage of spontaneously beating phenotype in differentiating EBs (Results shown: 
Mean 士 SEM’ n=3). *P<0.05, significantly different to the untreated control. 
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3.3 Effect of Exogenous Addition of H2O2 on Cardiac Differentiation 
3.3.1 Beating Profile of HzC^-treated EBs 
I 60- 丄 /O 
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o 4 ~ Z / Z 丨 , 1 1 1 1 1 
0 2 4 6 8 10 12 14 16 
Days of differentiation ("7+x") 
Fig.ll: A beating profile of control and HsCh-tfeated samples. EBs were treated with 
3 different concentrations (InM, lOOnM and lOfiM) of H2O2. Percentage of beating 
EBs was monitored from day 7+1 to day 7+15. As compared to the control, an 
exogenous addition of H2O2 led to an earlier appearance of spontaneously beating 
phenotype in differentiating EBs (Results shown: Mean 士 SEM’ n=3). *P<0.05 and 
**P<O.OI, significantly different to the untreated control. 
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3.3.2 mRNA Expression of Cardiac Structural Genes 
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Fig. 12(a): The mRNA expression of a-MHC following treatment with different 
concentrations of H2O2. A trend of upregulation of a-MHC expression was observed 
in H202-treatment as compared to the untreated control. (Results shown: Mean 士 
SEM, n=3) 
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Fig. 12(b): The mRNA expression of C-actin following treatment with different 
concentrations of H2O2. A trend of upregulation of C-actin expression was observed in 
H202-treatment as compared to the untreated control (Results shown: Mean 士 SEM, 
n=3) 
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Fig. 12(c): The mRNA expression of a-actinin following treatment with different 
concentrations of H2O2. A trend of upregulation of a-actinin expression was observed 
in HsCh-tfeatment as compared to the untreated control. (Results shown: Mean 士 
SEM’ n=3) 
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Fig. 12(d): The mRNA expression of cTnT following treatment with different 
concentrations of H2O2. A trend of upregulation of cTnT expression was observed with 
H202-treatment as compared to the untreated control. (Results shown: Mean 士 SEM, 
n=3) 
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3.3.3 Protein Expression of Cardiac Structural Genes 
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Fig. 13(a): The protein expression of a-MHC following treatment with different 
concentrations of H2O2. a-MHC expression was upregulated with HsCh-treatment as 
compared to the untreated control. The bar chart shows densitometric analyses of 
three independent experiments (Results shown: Mean 士 SEM), *P<0.05, significantly 
different to the untreated control. 
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Fig. 13(b): The protein expression of C-actin following treatment with different 
concentrations of H2O2. C-actin expression was upregulated with H202-treatment as 
compared to the untreated control. The bar chart shows densitometric analyses of 
three independent experiments (Results shown: Mean 士 SEM). *P<0.05’ significantly 
different to the untreated control. 
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Fig. 13(c): The protein expression of a-actinin following treatment with different 
concentrations of H2O2. a-actinin expression was upregulated with HsCh-treatment as 
compared to the untreated control The bar chart shows densitometric analyses of 
three independent experiments (Results shown: Mean 士 SEM), *P<0.05, significantly 
different to the untreated control. 
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Fig. 13(d): The protein expression of cTnT following treatment with different 
concentrations of H2O2. cTnT expression was upregulated with H202-treatment as 
compared to the untreated control. The bar chart shows densitometric analyses of 
three independent experiments (Results shown: Mean 士 SEM). *P<0.05, significantly 
different to the untreated control 
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Fig. 14(a): The mRNA expression of AP-1 on day 4 and day 7 following treatment with 
different concentrations of H2O2. With H202-treatment, AP-1 expression was 
increased on day 4 while remained similar to the untreated control on day 7 (Results 
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Fig. 14(b): The mRNA expression of HAND2 on day 4 and day 7 following treatment 
with different concentrations of H2O2. H202-treatment gave no significant change to 
the level of HAND2 expression on both day 4 and day 7 (Results shown: Mean 士 SEM, 
n=3). 
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Fig. 14(c): The mRNA expression of HANDl on day 4 and day 7 following treatment 
with different concentrations of H2O2. With H^Ch-treatment, HANDl expression was 
reduced on day 4 but increased on day 7 (Results shown: Mean 士 SEM，n=3). 
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Fig. 14(d): The mRNA expression of MEF2C on day 4 and day 1 following treatment 
with different concentrations of H2O2. With HsCh-treatment, MEF2C expression was 
increased on day 4 but decreased on day 7 (Results shown: Mean 士 SEM, n=3). 
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Fig. 14(e): The mRNA expression of Spl on day 4 and day 7 following treatment with 
different concentrations of H2O2. With FJ^Ch-treatment，Spl expression was increased 
on day 4 while remained similar to the untreated control on day 7 (Results shown: 
Mean 士 SEM, n=3). *P<0.05, significantly different to the untreated control. 62 
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Fig. 14(f): The mRNA expression of SRF on day 4 and day 7 following treatment with 
different concentrations of H2O2. With HiCh-treatment, SRF expression was increased 
on day 4 but decreased on day 7 (Results shown: Mean 士 SEM, n=3). *P<0.05 
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Fig. 14(g): The mRNA expression ofTbx5 on day 4 and day 7 following treatment with 
different concentrations of H2O2. H202-treatment gave no significant change to the 
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Fig. 14(h): The mRNA expression of GATA-4 on day 4 and day 7 following treatment 
with different concentrations of H2O2. With H202-treatment, GATA-4 expression was 
increased on day 4 and had a trend of increase on day 7 (Results shown: Mean 士 SEM， 
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Fig. 14(i): The mRNA expression of Nkx2.5 on day 4 and day 7 following treatment 
with different concentrations of H2O2. With HsCh-treatment’ Nkx2.5 expression was 
reduced on day 7 (Results shown: Mean 士 SEM, n 二3) *P<0.05, significantly different 
to the untreated control. 
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3.3.5 Protein Expression of Cardiac Transcription Factors 
1 2 3 1 2 3 
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AP-1 AP-1 + Peptide 
Fig. 15(a): Protein extracts of (!) day 4 EB, (2) day 7 EB and (3) embryonic heart 
were probed with AP-1 antibody at a 1:500 dilution with or without pre-incubation of 
antibody with peptide. Peptide pre-incubation revealed the position of target band as 
indicated by the arrow. 
1 2 3 1 2 3 二 寒 
SRF SRF + Peptide 
Fig. J5(h): Protein extracts of (I) day 4 EB, (2) day 7 EB and (3) embryonic hear! 
were probed with SRF antibody at a 1:500 dilution with or without pre-incubation of 
antibody with peptide. Peptide pre-incubation revealed the position of target bands as 
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Fig. 16(a) : The protein expression of AP-1 on day 4 and day 7 following treatment 
with different concentrations of H2O2. With HsCh-treatment’ AP-1 expression was 
increased on day 4 while remained similar to the untreated control on day 7. The bar 
charts show densitometric analyses of three independent experiments (Results shown: 
Mean 士 SEM，n=3). *P<0.05 significantly different to the untreated control. 
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Fig. 16(b): The protein expression of GATA-4 on day 4 and day 7 following treatment 
\vith different concentrations of H2O2. With HaCh-treatment, GATA-4 expression was 
increased on both day 4 and day 7. The bar charts show densitometric analyses of 
three independent experiments (Results shown: Mean 士 SEM，n=3). *P<0.05 and 
***P<0.001, significantly different to the untreated control. 
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Fig. 16(c): The protein expression of MEF2C on day 4 and day 7 following treatment 
with different concentrations of H2O2. With H202-treatment, MEF2C expression was 
increased on day 4 but decreased on day 7. The bar charts show densitometric 
analyses of three independent experiments (Results shown: Mean 士 SEM, n=3). 
*P<0.05, significantly different to the untreated control. 
70 
_ SRF-L 國 SRF-M 
2 . 0 - 1 
0 * 
？ 1.5- * * • 
a * -T- * ：：：：：： ** 
1 1-0- ™；；；；；； 旧旧 ；；；；；； 
a> ：：：：：： ：：：：：： liE：：： ：：：：：： 
< 0.5- I ; ; ；；;；； 
0.0 r l t t f f l — — — — ^ f f l _ — — — — — — ^ S 
CTL 10nM 100nM 1uM 
Day4 Samples 
CTL lOnM lOOnM luM CTL lOnM lOOnM luM 
SRF-L 费 丨 I 窗 r r . 二 
SRF-M 着 • 一 I 麵 麵 脚 〒 
b-tubulin I ^ ^ I f • •‘ '• I I 吻 教 
Day4 Day 7 
國 SRF-L • SRF-M 
CTL 10nM lOOnM 1uM 
Day/ Samples 
Fig. 16(d): The protein expression of SRF on day 4 and day 7 following treatment with 
different concentrations of H2O2. With Fl2(h-treatment，SRF-L expression was 
increased on day 4 but decreased on day 7, while SRF-M expression was increased on 
day 4 but remained unchanged on day 7. The bar charts show densitometric analyses 
of three independent experiments (Results shown: Mean 士 SEM, n=3). *P<0.05 and 
**P<0.01, significantly different to the untreated control. 
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Fig. 16(e): The protein expression of Spl on day 4 and day 7 following treatment with 
different concentrations of H2O2. With HsC^-treatment’ Spl expression was increased 
on day 4 but remained similar on day 7. The bar charts show densitometric analyses 
of three independent experiments (Results shown: Mean 士 SEM’ n=3). *P<0.05, 
significantly different to the untreated control. 
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Table 6: Summarized results of the mRNA and protein expression of cardiac 
transcription factors following H2O2 treatment 
Cardiac Exogenous H2O2 treatment 
transcription mRNA expression Protein expression 
factors Day 4 Day 7 Day 4 Day 7 
GATA-4 个 -- 个 个 
AP-1 个 -- 个 --
MEF2C t i t i 
SRF 个 i 个 i 
Spl 个 一 个 一 
HANDl i t UD UD 
HAND2 / / 
Nkx2.5 - I I I 
Tbx5 / / 
Key:"个 ’’ —increase; " | " - decrease; - ， ， - no change; "UD" - undetectable 
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3.3.6 Post-translational modifications of cardiac transcription factors 
1.6 
1 . 4 • * 
<U 1.2 - llllijilljll T- IHiT 'ill 
C . …0 it i 
( 0 1 • m H I " ! l i l l l l 1 i I • i 
€ 丨’ 
2 0.8 - i 
0.6 -
O) 
< 0 . 4 -
0.2 -
0 ~ m m m • m M M _ , _ L J — — _ . _ _ I L - i l i J _ . 
C T L l O n M l O O n M 1 u M 
Day4 Samples 
CTL iOnM 10_ luM CTL 10nM lOanM fuM 
AP-1 得麵麵藝 看 禱 眷 麵 
b4ubulin ^ ^ 麵 « w 窗 脚 _ 
Day 4 Day 7 
1.6「 女 
* * * 
1 . 4 - | — ^ 
0) 1.2 - * , O) [pT^ — 
re 1 - r ^ r , ‘ 
0 ‘ , 
T3 0.8 -丨丨I 丨丨，，丨 
t 0.6 - ||、 ，‘ 
1 0 . 4 - I I III i ,, 
0.2 - li � “ 丨丨： (i i Ml M ‘ 
0 丨丨丨.丨”,_"！ I I L _ _ L 
C T L l O n M l O O n M 1 u M 
Day7 Samples 
Fig. 17 (a): The protein expression of AP-1 in H202-treated day 4 and day 7 samples 
following de-phosphorylation. AP-1 expression was increased on both day 4 and day?. 
The bar charts show densitometric analyses of three independent experiments (Results 
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Fig. 17(b): The protein expression of GATA-4 in H202-treated day 4 and day 7 samples 
following de-phosphorylation. GATA-4 expression was increased on both day 4 and 
day?. The bar charts show densitometric analyses of three independent experiments 
(Results shown: Mean 士 SEM, n=3). *P<0.05 and **P<0.01, significantly different to 
the untreated control 
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Fig. 17(c): The protein expression of MEF2C in H202-treated day 4 and day 7 samples 
following de-phosphorylation. MEF2C expression was increased on day 4 but 
decreased on day?. The bar charts show densitometric analyses of three independent 
experiments (Results shown: Mean 士 SEM，n=3). *P<0.05, significantly different to 
the untreated control. 
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Fig. 17(d): The protein expression of SRF in H202-treated day 4 and day 7 samples 
following de-phosphorylation. Both SRF-L and SRF-M expression were increased on 
day 4 but decreased on day 7. The bar charts show densitometric analyses of three 
independent experiments (Results shown: Mean 士 SEM, n=3). *P<0.05 and 
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Fig. 17(e): The protein expression of Spl in H^Ch-treated day 4 and day 7 samples 
following de-phosphorylation. Spl expression had a trend of increase on day 4 but 
decrease on day 7. The bar charts show densitometric analyses of two independent 
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Fig. 18(a): The protein expression of AP-1 in H202-treated day 4 and day 7 samples 
following de-sumoylation. AP-1 expression was increased on both day 4 and day?. 
The bar charts show densitometric analyses of three independent experiments (Results 
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Fig. 18(b): The protein expression of GATA-4 in H202-treated day 4 and day 7 samples 
following de-sumoylation. GATA-4 expression was increased on both day 4 and day 7. 
The bar charts show densitometric analyses of three independent experiments (Results 
shown: Mean 士 SEM, n=3). *P<0.05, significantly different to the untreated control. 
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Fig. 18(c): The protein expression of MEF2C in H202-treated day 4 and day 7 samples 
following de-sumoylation. MEF2C expression was increased on day 4 but had a trend 
of decrease on day 7. The bar charts show densitometric analyses of three independent 
experiments (Results shown: Mean 士 SEM, n=3). *P<0.05 and **P<0.01, 
significantly different to the untreated control. 
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Fig. 18(d): The protein expression of SRF in HsCh-treated day 4 and day 7 samples 
following de-sumoylation. Both SRF-L and SRF-M expression were increased on day 
4 but decreased on day7. The bar charts show densitometric analyses of three 
independent experiments (Results shown: Mean 士 SEM, n=3). *P<0.05, significantly 
different to the untreated control. 
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Fig. 18(e): The protein expression of Spl in IhCh-treated day 4 and day 7 samples 
following de-sumoylation. Spl expression had a trend of increase on day 4 while 
remained similar on day?. The bar charts show densitometric analyses of two 
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Fig. 19(a): The protein expression of AP-1 in HaCh-treated day 4 and day 7 samples 
following de-glycosylation. AP-1 expression had a trend of increase on day 4 and M>as 
upregulated on day?. The bar charts show densitometric analyses of three 
independent experiments (Results shown: Mean 士 SEM, n=3). *P<0.05, significantly 
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Fig. 19(b): The protein expression of GATA-4 in f^Ch-treated day 4 and day 7 samples 
following de-glycosylation. GATA-4 expression was increased on both day 4 and day?. 
The bar charts show densitometric analyses of three independent experiments (Results 
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Fig. 19(d): The protein expression of SRF in H202-treated day 4 and day 7 samples 
following de-sumoylation. Both SRF-L and SRF-M expression were increased on day 
4 but decreased on day?. The bar charts show densitometric analyses of three 
independent experiments (Results shown: Mean 士 SEM, n=3). *P<0.05, significantly 
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Fig. 19(e): The protein expression of Spl in HsCh-treated day 4 and day 7 samples 
following de-glycosylation. Spl expression had a trend of increase on day 4 while 
remained similar on day?. The bar charts show densitometric analyses of two 
independent experiments (Results shown: Mean 士 SEM, n=2). 
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3.3.7. Translocation of cardiac transcription factors 
1.4-
I 1 .2 -
W - T - 卞 w 1 n 丁 
£ 
9" . . £771 ICnM lOOnM luM 
S 0-8-
S 0.6- NICX2.5 � 一 ~ 一 
X 
妾 0.4-




Control 10nM lOOnM 1uM 
Samples 
Fig. 20(a): The protein expression of Nkx2.5 in the nucleus on day 3 following 
treatment with different concentrations of H2O2. Nkx2.5 expression remained similar 
as compared to the untreated control. The bar charts show densitometric analyses of 
two independent experiments (Results shown: Mean 士 SEM, n=2). 
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Fig. 20(b): The protein expression ofNkx2.5 in the nucleus on day 4 following 
treatment with different concentrations of H2O2. Nkx2.5 expression remained similar 
as compared to the untreated control. The bar charts show densitometric analyses of 
two independent experiments (Results shown: Mean 士 SEM, n=2). 
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Fig. 20(c): The protein expression of Nkx2.5 in the nucleus on day 5 following 
treatment with different concentrations of H2O2. Nkx2.5 expression remained similar 
as compared to the untreated control The bar charts show densitometric analyses of 
two independent experiments (Results shown: Mean 士 SEM，n=2). 
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Fig. 20(d): The protein expression of Nkx2.5 in the nucleus on day 6 following 
treatment with different concentrations of H2O2. With H202-treatment, nuclear Nkx2.5 
expression has a trend of increase as compared to the untreated control. The bar 
charts show densitometric analyses of two independent experiments (Results shown: 
Mean 士 SEM, n=2). 
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Fig. 20(e): The protein expression of Nkx2.5 in the nucleus on day 7 following 
treatment with different concentrations of H2O2. Nkx2.5 expression remained similar 
as compared to the untreated control. The bar charts show densitometric analyses of 




.2 1 2 - ~ r 
«0 
e 1 . 0 - — — 
a 
• 0 . 8 -
< 0.6 • 
H 
< Q CTL lOnM lOOnM l u M 
0.2- GATA-4 ^ m m m m r n ^ 
0.0-LJ——L-l——LJ——U L_ 
Control 10nM lOOnM 1iiM ygp mammmmmm 
Day 3 
Fig.21(a): The protein expression of GATA-4 in the nucleus on day 3 following 
treatment with different concentrations of H2O2. With HsCh-treatment, nuclear 
GATA-4 expression has a trend of increase as compared to the untreated control The 
bar charts show densitometric analyses of two independent experiments (Results 
shown: Mean 士 SEM, n=2). 
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Fig.21(b): The protein expression of GATA-4 in the nucleus on day 4 following 
treatment with different concentrations of H2O2. GATA-4 expression remained similar 
as compared to the untreated control. The bar charts show densitometric analyses of 
two independent experiments (Results shown: Mean 士 SEM, n=2). 
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Fig.21(c): The protein expression of GATA-4 in the nucleus on day 5 following 
treatment with different concentrations of H2O2. GATA-4 expression remained similar 
as compared to the untreated control. The bar charts show densitometric analyses of 
two independent experiments (Results shown: Mean 士 SEM, n=2). 
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Fig.21(d): The protein expression of GATA-4 in the nucleus on day 6 following 
treatment with different concentrations of H2O2. GATA-4 expression remained similar 
as compared to the untreated control The bar charts show densitometric analyses of 
two independent experiments (Results shown: Mean 士 SEM, n=2). 
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Fig. 21(e): The protein expression of GATA-4 in the nucleus on day 7 following 
treatment with different concentrations of H2O2. With HaCh-treatment, nuclear 
GATA-4 expression has a trend of increase as compared to the untreated control. The 
bar charts show densitometric analyses of two independent experiments (Results 
shown: Mean 士 SEM, n=2). 
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CHAPTER FOUR DISCUSSION 
Despite the prevalence of ischemic heart disease today, practical approaches for 
effectively combating the disease are far from ideal. Revascularization techniques 
currently adopted such as angioplasty and thrombolytic agents can only mitigate the 
cause of injury but are unable to recover the myocardial infarcts (Schwarz et al., 
1982). In more severe cases, allogenic transplantation is the only treatment of choice, 
but the number of recipients tremendously outweighs that of donors (Hobson, 2000). 
Researches on xeno-transplantation and artificial mechanical heart may provide 
further alternatives, yet they are not significantly advanced for clinical applications. 
At present, the most promising option that is appearing on the horizon is stem cell 
transplantation therapy for the repair of damaged myocardium. In this regard, it is 
imperative to obtain efficient protocols for directing the differentiation of stem cells 
into cardiac lineage. Of particular interest among thousands of candidates for the 
development of useful protocols are members of ROS. Understanding the role of ROS 
as key mediators in signaling cascades for cardiac differentiation of mouse ES cells 
may provide us with valuable hints for favorably driving the differentiation event. 
During the past twenty years, numerous investigations have been working on 
understanding the signaling pathways that affect stem cell fate and differentiation, but 
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many clues underlying the molecular mechanism are still waiting to be unraveled. It is 
evident in recent years that, an enhanced production of ROS occurs during cardiac 
hypertrophy, which re-activates signaling pathways involved in embryonic heart 
development and induces re-expression of fetal gene programs to modulate cardiac 
growth (Kuwahara et al., 2003, Hare and Silverton, 2001). This provides us with 
further insight that ROS, acting as the intracellular messengers, may work in concert 
with a subset of cardiac transcription factors to mediate the differentiation of ES cells 
into cardiac lineage. 
4.1 Changes in the Level of Endogenous ROS During Cardiac Differentiation of 
Mouse ES Cells 
During the course of differentiation, our data demonstrate that the level of 
endogenous ROS is changing from day to day. Notably, ROS production was induced 
at times when ES cells were still undifferentiated, elevated gradually upon 
differentiation with peak production on post-differentiation day 3 to 4, when 
cardiomyogenesis starts to occur as reflected by the increase in cardiac transcription 
factors' expressions (Boheler et al., 2002). Intracellular ROS level dropped steadily 
from day 5 onwards, reaching an amount similar to that of undifferentiated state by 
day 7. 
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In consistence, increased ROS production is apparently a general event occurring 
in many cells prior to the initiation of differentiation programs, as are cases for 
endothelial cells and smooth muscle cells. It is well documented that the level of ROS 
increases when various growth factors and cytokines bind to their respective receptors 
to initiate cell proliferation and/or differentiation. Examples include angiotensin II 
(Ushio-Fukai et al., 1999), insulin-like growth factor I (IGF-I) (Krieger-Brauer and 
Kather, 1995)，fibroblast growth factor (b-FGF) (Lo and Cruz, 1995) as well as 
interleukin-lL (Bonizzi et al., 2000). Myriads of signaling cascades are interplaying 
with one another to introduce the necessary stimuli for cell proliferation and 
differentiation. It is therefore speculated that ROS participates in the cardiogenic 
differentiation program, possibly by initiating a variety of signaling cascades that in 
turn regulate the activity of transcription factors and genes involved in cardiac 
differentiation. This speculation is further supported by Sauer's work, demonstrating 
the involvement of ROS in cardiotropin-1 -induced cardiac differentiation of mouse 
ES cells (Sauer et al., 2004). 
4.2 H2O2 and NO Have Opposite Effects Towards Cardiac Differentiation 
We showed that exogenous administration of H2O2 to differentiating EBs at any 
experimental concentrations enhanced the spontaneous beating activity of EB 
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outgrowths. In contrast, exogenous addition of NO donor SNP (InM - 1 OOnM) did 
not exert any cardiogenic effect. SNP at 10|iM even suppressed the formation of 
spontaneously beating EBs. This suggested that different reactive species may have 
distinctive roles towards cardiac differentiation; one species may be contributed to 
stimulatory effect while the other responsible for suppressive effect. 
Previous study showed that incubation of EBs with the NOS inhibitors 
post-plating resulted in a pronounced differentiation arrest of cardiomyocytes, 
whereas this effect could be reversed by co-application of the NO donor (Bloch et al., 
1999). In yet another study, NOS gene transfer or exogenous application of NO was 
shown to promote cardiac differentiation of ES cells (Kanno et al., 2004). These 
studies indicate that NO has a positive role in cardiac differentiation, in contrast to our 
present findings. The discrepancies may be due to the different concentration of NO 
donor used and/or the time for NO donor treatment. Previous studies tested NO donor 
at a much higher concentration (200|iM) when compared with ours (lOpM). Since NO 
can react with superoxide to form peroxynitrite, we speculate that, in differentiating 
EBs, NO at low concentration reacts with superoxide and thereby decreases the 
amount of superoxide available for the formation of H2O2 by superoxide dismutase, 
resulting in reduced endogenous formation of H2O2 and leading to an attenuation of 
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cardiac differentiation. Also, previous study showed that in the early stage of ES cell 
differentiation, expression of NO synthase (NOS) isoform 1 (NOS-1) decreased 
abruptly while NOS-2 is detectable only after several days (Krumenacker et al., 2006); 
in addition, treatment with NOS inhibitor during the initial stage of cardiac 
differentiation in P19C16 cells (embryonic carcinoma cells capable of cardiac 
differentiation) potentiated cardiac differentiation (Danalache et al., 2007). Both 
studies suggested that endogenous NO production may not be necessary or may even 
negatively affect initial stage of differentiation, supporting our present findings that 
exposure to NO during early stage of differentiation (differentiation days 2-7) has 
detrimental impact on cardiac differentiation. 
Collectively, a fine control between different reactive oxygen (e.g. superoxide, 
H2O2) and reactive nitrogen (NO) species is necessary to regulate the differentiation 
event in a coordinated manner. 
4.3 Exogenous Addition of H2O2 Advances Differentiation of Mouse ES Cells into 
Cardiac Lineage 
Our present investigation shows that exogenous application of H2O2 can enhance 
cardiac differentiation of ES cells, which supports previous investigation by Sauer and 
coworkers (Sauer et a l , 1999). In this previous study, EBs were treated with H2O2 for 
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a short period (1 hour) on differentiation day 4 (Sauer et al., 1999). Cardiac 
differentiation was assessed by counting the percentage of spontaneously beating EBs 
and the beating area on day 2-3 after EB attachment. However, in this group's study, 
the formation of spontaneously beating EBs in fact reaches peak only on day 6 after 
EB attachment. Therefore, cardiac differentiation has not yet completed on the day of 
assessment. Meanwhile, it should be noted that not all of the cardiac cells would beat 
spontaneously; some cardiac cells (e.g. mature atrial and ventricular cells) do not 
spontaneously beat as they are electrical quiescent and beat only upon stimulation by 
action potential arrival. Taken these into account, assessment of cardiac differentiation 
by spontaneously beating activities on day 2-3 after plating may not fully represent 
cardiac differentiation. 
In our present investigation, differentiating EBs were treated with H2O2 for 
several days before EB attachment and EBs were collected at differentiation day 7+25, 
the time point at which cardiac differentiation has completed. Apart from advancing 
the beating activity of ES-cell derived cardiomyocytes early during differentiation, 
our data show further that H2O2 administration prominently upregulates the 
expression of cardiac specific markers including a-MHC, C-actin, a-actinin and cTnT 
in both mRNA and protein levels. An enhanced expression of these mature 
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cardiac-specific proteins upon HiOi-treatment provides evidence that H202-induced 
cardiomyogenesis is not transient but perpetual. This new piece of information clearly 
indicated that H2O2 treatment can be used to direct cardiac differentiation of ES cells. 
To dissect the molecular mechanism underlying HsOz-mediated cardiac 
differentiation, we next looked further downstream at the expression of several 
cardiac transcription factors with H2O2 administration. All of the nine transcription 
factors studied here have been previously shown to be critically involved in 
embryonic heart development. Among these transcription factors, H202-treatment 
displayed no observable effect on the mRNA expression of HAND2 and Tbx5, 
suggesting that their transcriptional controls may not be ROS-sensitive. On the one 
hand, addition of H2O2 resulted in a remarkable increase in mRNA expression of AP-1, 
MEF2C, Spl, SRF and GATA-4 on day 4 as well as HANDl on day 7 post 
differentiation. However, a decrease was observed for treatment groups in mRNA 
expression of HANDl on day 4 as well as MEF2C, SRF and Nkx2.5 on day 7 post 
differentiation. Interestingly, H202-treatment appears to promote the expression of 
HANDl at a later time point of differentiation as compared with other cardiac 
transcription factors. It may be due to the fact that HANDl plays a role in later 
cardiac differentiation (Srivastava et al., 1995); alternatively, it is the expression of 
101 
other cardiac transcription factors that switches on its expression thereafter, since the 
expression level of HAND 1 was prominently reduced in the heart of Nkx2.5-deficient 
embryos (Akazawa and Komuro, 2003) and SRF-knockout mice (Niu et al., 2008), 
suggesting that these transcription factors can affect the expression level of HAND 1. 
In consistence, the protein expression of various transcription factors (those that were 
detectable by western blot) upon H202-treatment displayed similar profiles to their 
corresponding mRNA expression profiles. 
When representing the expression event graphically (Fig. 17), it can be 
speculated that H2O2 administration seems to have shifted the whole expression 
program forward, that gives rise to an advance in cardiac differentiation of ES cells. 
This further explains the enhancement in the spontaneous beating activity of EB 
outgrowths upon H2O2 treatment early during differentiation. These data clearly 
demonstrate that cardiac differentiation of mouse ES cells is critically dependent on 
the intracellular redox state of differentiating EBs. ROS may either directly act on the 
level of the transcription factors, or interfere with upstream signaling cascades to 
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Fig. 22: A graphical representation showing the expression events of transcription 
factors during cardiac differentiation 
4.4 Possible Role of H2O2 in Mediating Cardiac Differentiation of Mouse ES 
Cells 
Though the participation of ROS in signal transduction has been extensively 
studied, its exact molecular targets are not defined yet, in particular during 
cardiogenesis. An exogenous addition of H2O2 has been found to stimulate the 
mitogen-activated protein kinase (MAPK) pathways in different cell types (Lee et al., 
2009, Fischer et al., 2005, Han et al., 2005), specifically the extracellular regulated 
kinase 1/2 (ERK 1/2) pathway (Kim et al., 2006), c-Jun N-terminal kinase (JNK) 
pathway (Liu et a l , 2002) as well as p38 MAPK pathway (Bundy et a l , 2005, 
Ushio-Fukai et a l , 1998). Although the MAPK signaling pathways are apparently 
modulated by ROS, the respective tyrosine kinases are not the direct targets of ROS. 
It is the activity of the upstream tyrosine phosphatases that is redox-regulated 
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(Salmeen et al., 2003，Biswas et al., 2006). The messenger action of ROS is thought to 
lie on its ability to react with the cysteine residues of target proteins (Cross and 
Templeton, 2006). Containing cysteine residues prone to oxidation, ROS-dependent 
inhibition of phosphatases results in increased phosphorylation events, which in turn 
can activate a variety of downstream processes. For instance, both the translocation 
and the promoter binding activity of transcription factors can be altered by their 
phosphorylation state and therefore, modulation of target gene expression can occur 
(Treisman, 1996, Hagiwara, 2000). 
The activity of transcription factors is often modulated by post-translational 
modification, such as phosphorylation, sumoylation and glycosylation {Fig. 23). Such 
modifications rapidly and reversibly regulate the functions of transcription factors in 
the scope of subcellular localization, interaction with cofactors as well as 
transcriptional activation (Tootle and Rebay, 2005). ROS has been implicated to 
influence certain key players of these modification processes such as tyrosine 
phosphatases (Salmeen and Barford, 2005), SUMO-conjugating enzymes (Bossis and 
Melchior, 2006) and glycosylation enzymes (Wells et al., 2001), thereby regulate 
post-translational modification to a certain extent. However, preliminary data from 
de-phosphorylation (Fig. 17a-e), de-sumoylation {Fig. 18a-e) as well as 
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de-glycosylation {Fig.l9a-e) assays showed that the cardiac transcription factors 
studied were not modified post-translationally via phosphorylation, sumoylation or 
N-linked glycosylation . Further experiments are needed to confirm whether the 
cardiac transcription factors under investigation are activated via post-translational 
modifications during differentiation. 
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Fig. 23: A schematic diagram showing the possible roles of ROS in modulating the 
activity of transcription factors 
Apart from activating the members of signaling cascades involved in 
proliferation and differentiation, ROS may directly regulate the activity of 
transcription factors {Fig. 23). Redox regulation has been implicated on several 
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well-studied transcription factors including AP-1 (Abate et al., 1990, Okuno et al., 
1993)，nuclear factor K - B ( N F - K B ) (Schreck et al., 1991, Schreck et al., 1992), 
hypoxia-inducible factor (HIF-la) (Wang et al., 1995), c-Myb (Guehmann et al., 1992) 
as well as p53 (Rainwater et al., 1995). Many of these redox-sensitive transcription 
factors have a highly conserved cysteine residue located within their DNA-binding 
domains, which has to be modified for favorable binding to DNA (Abate et al., 1990). 
Similarly, the activity of cardiac transcription factors under the present investigation 
may also be modulated by the oxidizing effect of ROS on cysteine residue(s). 
Our findings provide substantial evidence that ROS participates in the cardiac 
differentiation of mouse ES cells. The elevated expression and potential elevated 
activity of various cardiac transcription factors upon H2O2 administration are thought 
to enhance the expression of cardiac structural proteins. These transcription factors 
either mediate the expression of target genes on its own, or act synergistically with 
one another to perform their work. For instance, the potent cardiac transcription 
factors GATA-4 and MEF2C directly binds to the promoters of the a-MHC and cTnl 
genes and switch on their expression (Molkentin et al., 1994, Charron et al., 1999) 
(Murphy et al., 1997, Di Lisi et al., 1998, Bhavsar et al., 2000) ； while Spl works 
collaboratively with MEF2C for optimal promoter activation of cTnT (Azakie et al., 
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2006). The promoter region of the C-actin gene contains four conserved CArG boxes, 
to which SRF recruits GATA-4 to cooperatively activate gene expression (Sepulveda 
et al., 1998) (Chen et al., 1996) . Further, at least two essential protein binding motifs 
corresponding to the transcription factors Nkx2.5 and SRF were identified in the 
promoter region of the a-actinin gene (Chen and Schwartz, 1996), indicating their 
roles in activation of gene expression. These analyses provide solid explanation to the 
enhanced expression of cardiac structural proteins, which is attributed to the 
ROS-mediated up-regulation in the expression of cardiac transcription factors. 
Indeed, to the best of our knowledge, this is the first molecular demonstration 
that an exogenous H2O2 treatment during ES cell differentiation would lead to an 
elevated expression of AP-1, SRF and Spl on Day 4 as well as HANDl on Day 7, 
apart from other well-studied cardiac transcription factors (e.g. GATA-4, MEF2C) 
(Sauer et al., 1999). Such an up-regulation is likely contributing to the enhanced 
expression of cardiac structural proteins exhibited later at day 7+25 post 
differentiation. Our investigation is a full profile one, which has monitored the whole 
differentiation event of mouse ES cells into cardiac lineage. These findings can 
hopefully lay the foundation for developing strategies to efficiently isolate ES-cell 
derived cardiomyocytes with high yield. 
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4.5 Future Directions 
To further understand the role that ROS might play in mediating cardiac 
differentiation of mouse ES cells, we are going to identify the signaling cascades as 
well as the key participants involved in the differentiation process. For instance, the 
endogenous levels of candidate kinase (e.g. ERK, JNK and P38 MAPK) during 
differentiation can be examined. Meanwhile, the effect of exogenous H2O2 addition 
on the expression on kinases can be followed. Pharmacological inhibitors or 
antagonists of key kinases in various signaling pathways can also be employed to 
study their effects on cardiogenesis. Impairment on cardiac differentiation will be 
observed if the corresponding kinase does play a role in mediating the differentiation 
process. In addition, the levels of phosphorylated cardiac transcription factors upon 
H2O2 treatment can be evaluated using specific antibodies. 
Since sumoylation and glycosylation are scarcely studied in ES cells, it is of 
great novelty to investigate if these two processes participate in mediating the 
differentiation of mouse ES cells into cardiac lineage. Firstly, the endogenous levels 
of both sumo-conjugating enzymes (El, E2 and E3) and glycosylation enzymes 
(0-GlcNAc transferase) during differentiation will be examined. As these enzymes 
have been implicated to be redox-sensitive in other cell populations (Wells et al., 
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2001), the effect of exogenous H2O2 administration on the expression of these 
enzymes in ES cells will be followed. If these processes are discovered to play roles 
in ROS-mediated cardiac differentiation, we will then investigate if there is 
modification of cardiac transcription factors by SUMO conjugates or 0-linked 
glycans using in vitro sumoylation assay (Collavin et al., 2004) and in vitro 
glycosylation (Golks et al., 2007) assay respectively. 
Furthermore, we would like to study the underlying mechanism of 
ROS-mediated up-regulation of cardiac transcription factors and structural genes. 
Using bioinformatics, detailed information on the promoter regions of various cardiac 
markers can be predicted, which can provide us with insights on the activation 




During the course of differentiation, the level of endogenous ROS is found 
changing from day to day, with peak production on post-differentiation day 3 to 4, 
when cardiomyogenesis starts to occur. Hypothesizing the potential participation of 
ROS in the cardiogenic differentiation program, an exogenous administration of H2O2 
to differentiating EBs enhanced the spontaneous beating activity of EB outgrowths. In 
contrast, exogenous addition of NO donor SNP at low concentration did not exert any 
cardiogenic effect, while the formation of spontaneously beating EBs was even 
suppressed at high concentration. This suggested that different reactive species might 
have distinctive roles towards cardiac differentiation. Further, an enhanced expression 
of mature cardiac-specific markers in both mRNA and protein levels upon 
H202-treatment provides evidence that EbOi-induced cardiomyogenesis is not 
transient but perpetual. In consistence, a prominent up-regulation of cardiac 
transcription factors in both mRNA and protein levels were also observed. These 
findings provide substantial evidence that ROS participates in the cardiac 
differentiation of mouse ES cells，possibly by initiating a variety of signaling cascades 
that in turn regulate the expression/activity of transcription factors and genes involved 
in cardiac differentiation. 
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